MergerBrief Daily: Deal News ARGX/FBRX: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its
MergerBrief Daily: Deal News ARGX/FBRX: argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline (PR) BCO/NATL: Malaysia Business Accounting Change; Revenue Impact ~$100M (PR) MOBX/PRSO: Nasdaq Minimum Bid Price Deficiency Notice; Annual Meeting Set Septemb